/
CRMD
$7.64-$0.21 (-2.68%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$615.8M
78M shares
52-week range
$6.13 – $14.96
17% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.72%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$0.78
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $429.8K | $283.3K | $239.2K | $190.9K | $65.4K | $0 | $43.5M | $311.7M |
| Cost of revenue | $396.8K | $373.2K | $204.8K | $148.9K | $3.7K | $205.6K | $3.2M | $36.0M |
| Gross profit | $33.0K | −$90.0K | $34.4K | $42.0K | $61.7K | −$205.6K | $40.3M | $275.7M |
| Gross margin | 7.7% | -31.8% | 14.4% | 22.0% | 94.3% | — | 92.7% | 88.5% |
| R&D | $18.8M | $11.1M | $13.4M | $13.1M | $10.7M | $13.2M | $3.9M | $19.3M |
| Operating income | −$26.9M | −$21.0M | −$27.2M | −$29.4M | −$30.6M | −$49.0M | −$22.4M | $150.1M |
| EBITDA | −$26.8M | −$20.9M | −$27.0M | −$29.4M | −$30.1M | −$46.2M | −$19.0M | $167.8M |
| Net income | −$26.8M | −$16.4M | −$22.0M | −$28.2M | −$29.7M | −$46.3M | −$17.9M | $163.1M |
| Net margin | -6242.4% | -5801.3% | -9207.7% | -14774.7% | -45409.9% | — | -41.2% | 52.3% |
| EPS (diluted) | -1.51 | -0.68 | -0.77 | -0.75 | -0.74 | -0.91 | -0.30 | 2.04 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $334M | $0.50 | $0.48–$0.51 | 4 |
| 2027 | $285M | $0.09 | $0.00–$0.17 | 4 |
| 2028 | $346M | $0.43 | $0.28–$0.52 | 4 |
| 2029 | $437M | $0.95 | $0.95–$0.96 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.53
Price
$7.64
Implied downside
-67%
Peer comparison
CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
www.cormedix.com- Employees
- 191
- IPO / List date
- May 13, 2010
- HQ
- PARSIPPANY, NJ
Held by traders on TradeandTell
No one on the platform currently holds CRMD.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-06-30 | 152,200 | $1.9M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2019-03-26 | 1-for-5reverse |
Recent trades on TradeandTell
No one on the platform has traded CRMD yet.
